PA8841801A1 - Métodos para utilizar composiciones de aminopiridina de liberación sostenida - Google Patents

Métodos para utilizar composiciones de aminopiridina de liberación sostenida

Info

Publication number
PA8841801A1
PA8841801A1 PA20098841801A PA8841801A PA8841801A1 PA 8841801 A1 PA8841801 A1 PA 8841801A1 PA 20098841801 A PA20098841801 A PA 20098841801A PA 8841801 A PA8841801 A PA 8841801A PA 8841801 A1 PA8841801 A1 PA 8841801A1
Authority
PA
Panama
Prior art keywords
methods
compositions
aminopiridine
sustained release
use sustained
Prior art date
Application number
PA20098841801A
Other languages
English (en)
Spanish (es)
Inventor
R Blight Andrew
Cohen Ron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41799491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8841801(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of PA8841801A1 publication Critical patent/PA8841801A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PA20098841801A 2008-09-10 2009-09-10 Métodos para utilizar composiciones de aminopiridina de liberación sostenida PA8841801A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9579708P 2008-09-10 2008-09-10

Publications (1)

Publication Number Publication Date
PA8841801A1 true PA8841801A1 (es) 2010-06-28

Family

ID=41799491

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098841801A PA8841801A1 (es) 2008-09-10 2009-09-10 Métodos para utilizar composiciones de aminopiridina de liberación sostenida

Country Status (15)

Country Link
US (3) US20100061935A1 (OSRAM)
EP (1) EP2343976A4 (OSRAM)
JP (1) JP2012502103A (OSRAM)
CN (1) CN101827522A (OSRAM)
AR (1) AR073573A1 (OSRAM)
AU (1) AU2009291781A1 (OSRAM)
BR (1) BRPI0903914A2 (OSRAM)
CA (1) CA2736381A1 (OSRAM)
CL (1) CL2009001841A1 (OSRAM)
PA (1) PA8841801A1 (OSRAM)
PE (1) PE20100264A1 (OSRAM)
RU (1) RU2011113762A (OSRAM)
TW (1) TW201010703A (OSRAM)
UY (1) UY32109A (OSRAM)
WO (1) WO2010030755A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
US20130210866A1 (en) * 2012-02-13 2013-08-15 Acorda Therapeutics, Inc. Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
DE102012103179A1 (de) 2012-04-12 2013-10-17 Sieber Forming Solutions Gmbh Verfahren und Vorrichtung zur spanlosen Herstellung eines Außengewindes auf Werkstücken aus Metall
UY34896A (es) * 2012-07-12 2014-02-28 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
WO2014028387A1 (en) * 2012-08-13 2014-02-20 Acorda Therapeutics, Inc. Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
CN104091062A (zh) * 2014-07-03 2014-10-08 刘鸿 基于检验效能的诊断性试验Meta分析的方法
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
HRP20250396T1 (hr) 2016-08-31 2025-05-23 Mapi Pharma Ltd. Depo sustavi koji sadrže glatiramer acetat
AU2018242998B2 (en) 2017-03-26 2023-11-02 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200462B (OSRAM) * 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US6284473B1 (en) * 1995-10-02 2001-09-04 Uab Research Foundation P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status
AU2004226876A1 (en) * 2003-04-03 2004-10-14 Prana Biotechnology Ltd Treatment of neurological conditions
WO2005011605A2 (en) * 2003-08-01 2005-02-10 Medarex, Inc. Combination therapies for multiple sclerosis
US8354437B2 (en) * 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
US20060276537A1 (en) * 2005-06-01 2006-12-07 Tamar Goren Use of ladostigil for the treatment of multiple sclerosis
EP1940285B1 (en) * 2005-09-23 2019-05-29 Acorda Therapeutics, Inc. Method, apparatus and software for identifying responders in a clinical environment

Also Published As

Publication number Publication date
RU2011113762A (ru) 2012-10-20
BRPI0903914A2 (pt) 2015-07-21
PE20100264A1 (es) 2010-04-28
CN101827522A (zh) 2010-09-08
UY32109A (es) 2010-04-30
AR073573A1 (es) 2010-11-17
WO2010030755A1 (en) 2010-03-18
CA2736381A1 (en) 2010-03-18
CL2009001841A1 (es) 2011-02-18
AU2009291781A1 (en) 2010-03-18
US20130072527A1 (en) 2013-03-21
EP2343976A4 (en) 2011-12-14
JP2012502103A (ja) 2012-01-26
US20100061935A1 (en) 2010-03-11
TW201010703A (en) 2010-03-16
US20130330277A1 (en) 2013-12-12
EP2343976A1 (en) 2011-07-20

Similar Documents

Publication Publication Date Title
PA8841801A1 (es) Métodos para utilizar composiciones de aminopiridina de liberación sostenida
CL2016001580A1 (es) Uso de compuestos derivados de indol para tratar una infección por flavivirus; compuestos derivados de indol; composiciones farmacéuticas; y uso de una combinación.
UY32292A (es) Agonistas de s1p1 y métodos de preparación y uso
CR20110135A (es) INHIBIDORES DE cMET
CR20140180A (es) Inhibidores macrocíclicos de serina proteasas de hepatitis c
HN2011000076A (es) Derivados de piridino-piridinonas, su preparacion.
MX386852B (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus metodos de uso.
ECSP12011654A (es) Derivados de 5-fluoropirimidinona
CL2012000258A1 (es) Proceso para la preparacion de composicion de aglomerante hidraulico asperjable que contiene como principales componentes agua, agregados, aglomerante hidraulico, acelerador de fraguado, aglomerante hidraulico asperjable; composicion; y uso
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
CL2011000098A1 (es) Uso de una betadefensina de mamifero para tratar enfermedad inflamatoria.
SV2009003300A (es) Nuevos herbicidas
DOP2010000351A (es) Activadores de glucoquinasa
UY32728A (es) Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia
CL2012000508A1 (es) Composicion para la aplicacion en cultivos agricolas al aire libre o invernaderos que comprende zeolita, y aditivos; uso de la composicion para aumentar el rendimiento de los cultivos agricolas.
SV2010003593A (es) Nuevos herbicidas
ECSP099791A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparación y su aplicación en terapéutica
ECSP12011651A (es) Derivados de 5-fluoro-2-oxopirimidina-1(2h)-carboxilato
TR201908180T4 (tr) N1-asil- 5-floropirimidinon deriveleri.
CL2013000734A1 (es) Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para bajar la presion intraocular; kit farmaceutico.
CL2009001804A1 (es) Uso de un copolimero de vinilamina-vinilformamida y un portador para preparar una composicion destinada a fortalecer las fibras queratinosas.
CR11765A (es) Derivados de iminopiridina y su uso
EA201270089A1 (ru) 2-(3-алкилтиобензоил)циклогександионы и их применение в качестве гербицидов
CR10286A (es) Derivados de tetrahidronaftalina, procedimientos para prepararlos y su uso como antiinflamatorios